A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation

Transplantation

Volumn 87, Issue 9, 2009, Pages 1325-1329

  Tydén, Gunnar ^a,e   Genberg, Helena ^a   Tollemar, Jan ^a   Ekberg, Henrik ^b   Persson, Nils H ^b   Tufveson, Gunnar ^c   Wadström, Jonas ^c   Gäbel, Markus ^d   Mörnstedt, Lars ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b University Hospital   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

B cells; Renal; Rituximab; Transplantation

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; RITUXIMAB; STEROID; TACROLIMUS;

ADULT; AGED; ANEMIA; ARTICLE; BACTERIAL INFECTION; BK VIRUS; BK VIRUS NEPHROPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVING DONOR; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYCOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, CD20; CADAVER; DOUBLE-BLIND METHOD; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PLACEBOS; REOPERATION; SAFETY; SURVIVAL ANALYSIS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 67649607453     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181a235fd     Document Type: Article

References (9)

1. Zand MS. Therapeutic antibody agents for B-cell immunomodulation in renal transplantation. Transplantation 2007; 84: S11.
2. Salama AD, Pusey CD. Drug insight: Rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2006; 6: 221.
3. Becker YT, Samaniego-Picota M, Sollinger HW. The emerging role of rituximab in organ transplantation. Transpl Int 2006; 19: 621.
4. Tyde'n G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigenspecific immunoadsorption and rituximab. Transplantation 2003; 76: 730.
5. Genberg H, Kumlien G, Wennberg L, et al. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: A 3-year follow-up. Transplantation 2008; 85: 1745.
6. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31: 456.
7. Edward JCW, Szczepanski L, Szechinski J, et al. Efficacy of B-celltargeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572.
8. Genberg H, Hansson A, Wernerson A, et al. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006; 10: 2418.
9. Mitsuhata N, Fujita R, Ito S, et al. Delayed-onset neutropenia in a patient receiving rituximab as treatment for refractory kidney transplantation. Transplantation 2005; 80: 1355.